DIRS.INFO The most relevant business & tech news

☆ Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
▼ + stars: | 2024-09-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +15 min

In this article ESALY4523.T-JPBIIB Follow your favorite stocks CREATE FREE ACCOUNTHannah Yoon | The Washington Post | Getty ImagesLeqembi, an Alzheimer's drug from Biogen and Eisai , isn't a cure for the mind-damaging disease. The drug works in part by clearing toxic plaques in the brain called amyloid, a hallmark of Alzheimer's, according to its manufacturers. The Mayo Clinic's center, which began screening patients for Leqembi in October, has 50 to 60 patients currently taking the drug, according to Petersen. The Mayo Clinic's Alzheimer's center similarly stops dosing patients if ARIA appears on an MRI, according to Petersen. Meeks' neurologist, Dr. Wendell Helveston, said a follow-up MRI picked up one small area of bleeding in her brain that didn't cause any symptoms.

Persons: Hannah Yoon, Missie Meeks, Meeks, Leqembi, I'm, haven't, Julio Rojas, Patricia Waldrup, Biogen's, Alzheimer's, Brian B, Bettencourt, Tracey Collins, Collins, Alex Scott, Scott, Medicare enrollees, Neurologists, Ronald Petersen, Jay Reinstein, Michael Robinson Chávez, Petersen, Michael Irizarry, Eisai's, Eisai, Biogen, Eisai's Scott, It's, Rojas, Wendell Helveston, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Washington Post, Getty, CNBC, University of California, San, San Francisco Health, Toronto Star, Medicare, Mayo Clinic Alzheimer's Disease Research, Georgetown University Hospital, Washington , D.C, Mayo, Leqembi, Mayo Clinic, Reuters, ARIA, Hattiesburg Clinic, Ave Locations: Biogen, Ellisville , Mississippi, U.S, San Francisco, Portland , Maine, Boston, South Mississippi, Washington ,, Mayo, Portland, South Portland, Mississippi, Eisai, Bartlett , Tennessee

In interviews, doctors at several other hospitals said they also used Burst’s products and expressed surprise that the F.D.A. Dr. Sandhu said he had used the product on at least 50 patients, thought it worked well and hadn’t detected any problems. He recalled that for some patients, insurance covered Burst treatment, which typically cost thousands of dollars. He said he would have notified patients had the F.D.A. He said he got off to a good start working for Dr. Härtl, but their standoff over the Burst research soured their relationship.

Persons: Faheem, Sandhu, ”, Gadjradj, Härtl Organizations: Georgetown University Hospital, Weill Cornell Locations: New York

☆ Medicare proposes removing limit on PET scans used to help diagnose Alzheimer's disease
▼ + stars: | 2023-07-18 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

Right now, the program for seniors will only cover one PET scan per lifetime for patients participating in clinical trials. The Medicare proposal would allow regional organizations, called Medicare Administrative Contractors, to decide whether to cover the diagnostic tool. It is still unclear when the decision on PET scans will be finalized. PET scans are a crucial diagnostic tool that detect an amyloid protein on the brain that is associated with Alzheimer's disease. People on Medicare generally pay 20% of the cost of a PET scan after meeting their deductible.

Persons: Jay Reinstein, Chiquita Brooks, LaSure Organizations: Georgetown University Hospital, Contractors, Centers, Medicare, Services Locations: Washington , DC, U.S

☆ I was a scholarship kid at an elite boarding school. It changed my life, but I'd never send my own kids away.
▼ + stars: | 2023-07-14 | by ( Elle Hardy | ) www.businessinsider.com time to read: +7 min

Kelly Johnson-Arbor said boarding school stabilized her life and helped her overcome shyness. While she had a positive experience, she decided not to send her own children to boarding school. The school gave me extra confidence and a great education, but I don't think boarding school is the right fit for everyone. She had friends who sent their kids to boarding schools, and she wanted me to have that experience. My children are 10 and 12, and given their more comfortable upbringing, I couldn't picture sending them away to boarding school.

Persons: Kelly Johnson, Arbor, Phillips, didn't, Phillips Exeter, I'd, I'm, weren't, Exeter, I've Organizations: Phillips Exeter, Service, Capital Poison Center, MedStar Georgetown University Hospital, Phillips Exeter Academy, Niche, East Coast, Andover, Harvard Locations: Wall, Silicon, Washington , DC, America, Anchorage , Alaska, Exeter , New Hampshire, Alaska, Exeter

☆ I went to Phillips Exeter, one of the most elite boarding schools in America. It changed my life, but I wouldn't send my kids there.
▼ + stars: | 2023-07-14 | by ( Elle Hardy | ) www.businessinsider.com time to read: +7 min

While she had a positive experience, she decided not to send her own children to boarding school. I went to Phillips Exeter Academy , which is ranked by Niche as the third-best boarding high school in America . The school gave me extra confidence and a great education, but I don't think boarding school is the right fit for everyone. She had friends who sent their kids to boarding schools, and she wanted me to have that experience. My children are 10 and 12, and given their more comfortable upbringing, I couldn't picture sending them away to boarding school.

Persons: Kelly Johnson, Arbor, Phillips, didn't, Phillips Exeter, I'd, I'm, weren't, Exeter, I've Organizations: Service, Capital Poison Center, MedStar Georgetown University Hospital, Phillips Exeter Academy, Niche, East Coast, Andover, Harvard Locations: Wall, Silicon, Washington , DC, America, Anchorage , Alaska, Exeter , New Hampshire, Alaska, Exeter

☆ Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
▼ + stars: | 2023-07-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Sales of the Alzheimer's drug Leqembi may be slow initially due to logistical requirements but could pick up in 2024, analysts said after the groundbreaking treatment won approval in the U.S.Wall Street is chewing over the Food and Drug Administration's Thursday approval of Leqembi – a milestone in the treatment of the disease, even though the drug isn't a cure. Leqembi, from drugmakers Eisai and Biogen , is the first medicine proven to slow the progression of Alzheimer's in people at the early stages of the memory-robbing disease. Yee added that the firm's channel checks suggest doctors see the registry requirement "as a potential real-world challenge – at least in the initial phase." That includes navigating Medicare's registry requirement and coordinating PET scans and MRIs to screen for dangerous side effects of the drug. But Goodman, like other analysts, also noted that "we continue to expect a slow ramp in 2023 and acceleration moving into 2024."

Persons: Jay Reinstein, drugmakers, Yatin Suneja, Jefferies, Michael Yee, Yee, Paul Matteis, Marc Goodman, Goodman Organizations: Georgetown University Hospital, Wall, Food, Leqembi, FDA, National Institute, Aging, ARIA, SVB Securities Locations: Washington , DC, U.S

☆ Her dad was diagnosed with cancer. This teen has donated thousands of books to kids in hospitals
▼ + stars: | 2023-05-07 | by ( Faith Karimi | ) edition.cnn.com time to read: +9 min

At the age of 17, Emily launched a neighborhood book drive in honor of her dad, Mike Bhatnagar. Her initial goal was to collect books for children undergoing cancer treatment, but she’s expanded it to all patients under 18. The neighborhood book drive that began with a lone teen in a cloud of despair over her dad’s illness has grown into a nationwide initiative. “We are grateful to have been chosen by Emily … Hospitals are a scary place for kids, and the books will help enhance the healing environment.”Whenever possible, Emily specifies the books go to hospitals with pediatric cancer units. Her not-so-little book drive is teaching her how to run a nonprofit and build relationships with community leaders.

☆ Rep. Jamie Raskin Undergoes Treatment for Lymphoma
▼ + stars: | 2022-12-29 | by ( Eliza Collins | ) www.wsj.com time to read: 1 min

Rep. Jamie Raskin said he had been diagnosed with lymphoma and would undergo a course of chemo-immunotherapy on an outpatient basis. Rep. Jamie Raskin of Maryland, a rising star in the Democratic Party who recently played a central role in the House investigation into the Jan. 6, 2021 Capitol riot, said he has been diagnosed with lymphoma and has started treatment. Mr. Raskin, who is 60 years old and about to start his fourth term in Congress, said he had been diagnosed with Diffuse Large B Cell Lymphoma and would undergo a course of chemo-immunotherapy on an outpatient basis at Washington’s MedStar Georgetown University Hospital and Lombardi Comprehensive Cancer Center. He called it a “serious but curable” form of cancer and said people with his condition have an excellent prognosis after four months of treatment.

WASHINGTON, Dec 28 (Reuters) - Jamie Raskin, a Democratic U.S. lawmaker who rose to prominence as he oversaw former President Donald Trump's second impeachment trial in the House of Representatives, has been diagnosed with cancer, he said on Wednesday. "After several days of tests, I have been diagnosed with Diffuse Large B Cell Lymphoma, which is a serious but curable form of cancer," Raskin, 60, said in a statement released by his office. Raskin has also served on the January 6 Committee, which investigated the Capitol attack and Trump's role in it. In the next Congress, Raskin is set to serve as the top Democrat on the House Oversight panel. Raskin told MSNBC during an interview later on Wednesday that the chemotherapy treatments were scheduled to begin this week.

WASHINGTON, Dec 28 (Reuters) - Jamie Raskin, a Democratic U.S. representative who rose to prominence as the lead manager for former President Donald Trump's second impeachment trial, has been diagnosed with cancer, he said on Wednesday. "After several days of tests, I have been diagnosed with Diffuse Large B Cell Lymphoma, which is a serious but curable form of cancer," Raskin said in an official statement. Raskin has also served on the January 6 Committee, which investigated the Capitol attack and Trump's role in it. In the next Congress, Raskin is set to serve as the top Democrat on the House Oversight panel. Reporting by Gram Slattery in Washington Editing by Caitlin Webber and Matthew LewisOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Georgetown University Hospital"

10 mentions found